127 related articles for article (PubMed ID: 38307806)
1. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Mak KS; Scannell Bryan M; Dignam JJ; Shipley WU; Lin Y; Peters CA; Gore EM; Rosenthal SA; Zeitzer KL; D'Souza DP; Horwitz EM; Pisansky TM; Maier JM; Chafe SM; Robin TP; Roach M; Tran PT; Souhami L; Michalski JM; Hartford AC; Feng FY; Sandler HM; Efstathiou JA
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38307806
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
3. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
Kishan AU; Wang X; Sun Y; Romero T; Michalski JM; Ma TM; Feng FY; Sandler HM; Bolla M; Maingon P; De Reijke T; Neven A; Steigler A; Denham JW; Joseph D; Nabid A; Carrier N; Souhami L; Sydes MR; Dearnaley DP; Syndikus I; Tree AC; Incrocci L; Heemsbergen WD; Pos FJ; Zapatero A; Efstathiou JA; Guerrero A; Alvarez A; San-Segundo CG; Maldonado X; Xiang M; Rettig MB; Reiter RE; Zaorsky NG; Ong WL; Dess RT; Steinberg ML; Nickols NG; Roy S; Garcia JA; Spratt DE;
Eur Urol; 2022 Jul; 82(1):106-114. PubMed ID: 35469702
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Efstathiou JA; Bae K; Shipley WU; Hanks GE; Pilepich MV; Sandler HM; Smith MR
Eur Urol; 2008 Oct; 54(4):816-23. PubMed ID: 18243498
[TBL] [Abstract][Full Text] [Related]
5. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
Kishan AU; Wang X; Seiferheld W; Collette L; Sandler KA; Sandler HM; Bolla M; Maingon P; De Reijke T; Hanks GE; Nickols NG; Rettig M; Drakaki A; Reiter RE; Spratt DE; Kupelian PA; Steinberg ML; King CR
JAMA Oncol; 2019 Jan; 5(1):91-96. PubMed ID: 30326032
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
Kwak L; Ravi P; Armstrong JG; Beckendorf V; Chin JL; D'Amico AV; Dearnaley DP; Di Stasi SM; Gillessen S; Lukka H; Mottet N; Pommier P; Seiferheld W; Sydes MR; Tombal B; Zapatero A; Regan MM; Xie W; Sweeney CJ
J Clin Oncol; 2024 Jun; 42(18):2132-2138. PubMed ID: 38471051
[TBL] [Abstract][Full Text] [Related]
7. A Nomogram for Testosterone Recovery After Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
Spiegel DY; Hong JC; Oyekunle T; Waters L; Lee WR; Salama JK; Koontz BF
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):834-842. PubMed ID: 30419308
[TBL] [Abstract][Full Text] [Related]
8. Efficacy characteristics of different therapeutic modalities for locally advanced prostate cancer: a Bayesian network meta-analysis of randomized controlled trials.
Xue J; Wang Y; Zheng Y; Zhang J; Qi F; Cheng H; Si S; Li R; Li X; Qin Z; Yu B; Zou Q
Ann Transl Med; 2018 Sep; 6(18):358. PubMed ID: 30370285
[TBL] [Abstract][Full Text] [Related]
9. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
Ravi P; Xie W; Buyse M; Halabi S; Kantoff PW; Sartor O; Attard G; Clarke N; D'Amico A; Dignam J; James N; Fizazi K; Gillessen S; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ
Eur Urol; 2024 May; ():. PubMed ID: 38777647
[TBL] [Abstract][Full Text] [Related]
10. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy.
Son CH; Hamstra DA; Feng FY; Liauw SL
Am J Clin Oncol; 2017 Aug; 40(4):348-352. PubMed ID: 25436827
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
Butler SS; Mahal BA; Moslehi JJ; Nohria A; Dee EC; Makkar R; Whitbeck A; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2021 Jul; 127(13):2213-2221. PubMed ID: 33905530
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].
Sartor O; Karrison TG; Sandler HM; Gomella LG; Amin M; Purdy J; Michalski JM; Garzotto MG; Pervez N; Balogh AG; Rodrigues GB; Souhami L; Neil Reaume M; Williams SG; Hannan R; Jones CU; Horwitz EM; Rodgers JP; Feng FY; Rosenthal SA
Eur Urol; 2024 Jun; ():. PubMed ID: 38897867
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
14. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU; Pugh SL; Sandler HM; Chetner MP; Amin MB; Bruner DW; Zietman AL; Den RB; Leibenhaut MH; Longo JM; Bahary JP; Rosenthal SA; Souhami L; Michalski JM; Hartford AC; Amin PP; Roach M; Yee D; Efstathiou JA; Rodgers JP; Feng FY; Shipley WU
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):294-303. PubMed ID: 34481017
[TBL] [Abstract][Full Text] [Related]
15. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
Nabid A; Carrier N; Martin AG; Bahary JP; Lemaire C; Vass S; Bahoric B; Archambault R; Vincent F; Bettahar R; Duclos M; Garant MP; Souhami L
Eur Urol; 2018 Oct; 74(4):432-441. PubMed ID: 29980331
[TBL] [Abstract][Full Text] [Related]
16. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
17. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
[TBL] [Abstract][Full Text] [Related]
18. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
19. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
20. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
